OPG BioAssay(TM) ELISA Kit, Human

Sandwich ELISA quantitative detection kit for Human OPG in cell culture supernates, serum, plasma (heparin, EDTA), saliva and urine.\n\nOsteoprotegerin (OPG) is identical to osteoclastogenesis inhibitory factor (OCIF), a soluble member of the tumor-necrosis factor receptor family that inhibits osteoclastogenesis.1 OPG is considered to play an important role in the regulation of bone resorption by modifying osteoclast differentiation.2 Osteoprotegerin is an independent risk factor for the progression of atherosclerosis and onset of cardiovascular disease.3 It can act as a soluble factor in the regulation of bone mass and imply a utility for OPG in the treatment of osteoporosis associated with increased osteoclast activity.4 OPG system may play a critical role in the development of osteolytic bone disease in multiple myeloma and that targeting this system may have therapeutic potential.5 OPG also plays a role in the vascular system.6 The standard product used in this kit is recombinant OPG, a 55kD glycoprotein.\n\nAssay Range:\n93.7pg/ml-6000pg/ml\n\nSensitivity:\n< 5 pg/ml\n\nCrossreactivity:\nThere is no detectable cross-reactivity with other relevant proteins.\n\nUniprot ID:\nO00300\n\nEntrez Gene ID:\n4982\n\nKit Components:\n96-well plate pre-coated with anti-OPG, Human\nLyophilized recombinant OPG, Human standard, 10ng/tube, 2Ea\nUSB Cat No Kit Component\n143696 Avidin-Biotin-Peroxidase Complex (ABC), 130ul (1:100 dilution)\n143697 Sample diluent buffer, 30ml\n143698 Antibody diluent buffer, 12ml\n143699 ABC diluent buffer, 12ml\n143700 TMB color developing agent, 10ml\n143701 TMB stop solution, 10ml\n\nStorage and Handling:\nStore at 4 degrees C for 6 months, at -20 degrees C for 12 months. Avoid multiple freeze-thaw cycles.

Prices direct from United States Biological

Quick response times

Exclusive Biosave savings/discounts

SPECIFICATIONS

Catalog Number

143996

Size

96Tests

References

1. Yasuda, H.; Shima, N.; Nakagawa, N.; Mochizuki, S. I.; Yano, K.; Fujise, N.; Sato, Y.; Goto, M.; Yamaguchi, K.; Kuriyama, M.; Kanno, T.; Murakami, A.; Tsuda, E.; Morinaga, T.; Higashio, K. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 139: 1329-1337, 1998. \n2. Ohmori, H.; Makita, Y.; Funamizu, M.; Hirooka, K.; Hosoi, T.; Orimo, H.; Suzuki, T.; Ikari, K.; Nakajima, T.; Inoue, I.; Hata, A. Linkage and association analyses of the osteoprotegerin gene locus with human osteoporosis. J. Hum. Genet. 47: 400-406, 2002. \n3. Kiechl, S.; Schett, G.; Wenning, G.; Redlich, K.; Oberhollenzer, M.; Mayr, A.; Santer, P.; Smolen, J.; Poewe, W.; Willeit, J. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation 109: 2175-2180, 2004. \n4. Simonet, W. S.; Lacey, D. L.; Dunstan, C. R.; Kelley, M.; Chang, M.-S.; Luthy, R.; Nguyen, H. Q.; Wooden, S.; Bennett, L.; Boone, T.; Shimamoto, G.; DeRose, M.; and 19 others. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89: 309-319, 1997. \n5. Croucher, P. I.; Shipman, C. M.; Lippitt, J.; Perry, M.; Asosingh, K.; Hijzen, A.; Brabbs, A. C.; van Beek, E. J. R.; Holen, I.; Skerry, T. M.; Dunstan, C. R.; Russell, G. R.; Van Camp, B.; Vanderkerken, K. Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood 98: 3534-3540, 2001. \n6. Brandstrom, H.; Stiger, F.; Lind, L.; Kahan, T.; Melhus, H.; Kindmark, A. A single nucleotide polymorphism in the promoter region of the human gene for osteoprotegerin is related to vascular morphology and function. Biochem. Biophys. Res. Commun. 293: 13-17, 2002.\n